drugset / Trial / NCT06118866
A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks
Timeline
- Start
- 2023-09-11
- Primary completion
- 2024-08-26
- Completion
- 2024-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | HMI-115 | Monoclonal antibody | 120 mg | Subcutaneous |
| Comparator | HMI-115 | Monoclonal antibody | 240 mg | Subcutaneous |